Aspirin and temporal arteritis;Aspirine et maladie de horton

Journal des Maladies Vasculaires

Volumn 30, Issue 1, 2005, Pages 5-7

  Benhamou, Y ^a   Levesque H ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; DEXAMETHASONE; GAMMA INTERFERON; INDOMETACIN; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR DISEASE; CORTICOSTEROID THERAPY; EDITORIAL; EXTERNAL CAROTID ARTERY; PATHOPHYSIOLOGY; TEMPORAL ARTERITIS;

EID: 17444387134     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0398-0499(05)83791-6     Document Type: Short Survey

References (23)

1. WEYAND CM, GORONZY MD, PH D. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med, 2003; 139: 505-15.
2. NORDBORG E, BENGTSSON BA. Death rate and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. Br Med J, 1989; 299: 549-50.
3. UDDHAMMAR A, ERIKSSON AL, NYSTROM L, STENLING R, RANTAPAA-DAHLQVIST R. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in Northern Sweden. J Rheumatol, 2002; 29: 737-42.
4. MATTESON EL, GOLD KN, BLOCH DA, HUNDER GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med, 1996; 100: 193-6.
5. SAVE-SODERBERGH J, MALMWALL BE, ANDERSON R, BENGTSSON BA. Giant cell arteritis as a cause of death. JAMA, 1986; 255: 493-6.
6. CULLEN JP, COLEIRO JA. Ophtalmic complications of giant cell arteritis. Surv Ophtalmol, 1976; 20: 247-60.
7. HAYREH SS. Ophtalmic features of giant cell arteritis. Clin Rheumatol 1991; 3: 431-59.
8. CASELLI RJ, HUNDER GG, WHISNANT JP. Neurologic disease in biopsy proven giant cell (temporal) arteritis. Neurology, 1988; 38: 352-9.
9. AIELLO PD, TRAUTMANN JC, MCPHEE TJ, KUNSELMAN AR, HUNDER GG. Visual prognosis in giant cell arteritis. Ophtalmology, 1993; 4: 550-5.
10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324: 71-86.
11. LÉVESQUE H. L'aspirine en prévention primaire de la maladie athéromateuse: des indices mais encore des incertitudes. J Mal Vasc, 2002; 27: 263-6.
12. WEYAND CM, KAISER M, YANG H, YOUNGE B, GORONZY JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum, 2002; 46: 457-66.
13. BRACK A, GEISLER A, MARTINEZ-TABOADA VM, YOUNGE BR, GORONZY JJ, WEYAND CM. Giant cell vasculitis is a T cell-dependent disease. Mol Med, 1997; 3: 530-43.
14. BRACK A, MARTINEZ-TABODA V, STANSON A, GORONZY JJ, WEYAND CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum, 1999; 42: 311-7.
15. WEYAND CM, TEZLAFF N, BJORNSSON J, BRACK A, YOUNGE B, GORONZY JJ. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum, 1997; 40: 19-26.
16. KAISER M, WEYAND CM, BJORNSSON J, GORONZY JJ. Platelet-derived growth factor, intimai hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum, 1998; 41: 623-33.
17. DUHAUT P, BOSSHARD S, SALLE V et al. Facteurs prédictifs de cécité et de troubles visuels dans la maladie de Horton. Rev Med Interne, 2003; 24: (Suppl 1): 50-1.
18. LIOZON E, HERMANN F, LY K et al. Facteurs prédictifs de complications céphaliques ischémiques irréversibles au cours de la maladie de Horton: étude prospective sur 178 patients. Rev Med Interne, 2001; 22: 30-41.
19. LIOZON E, HERMANN F, LY K et al. Risk factors of visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med, 2001; 111: 211-7.
20. GONZALEZ-GAY MA, BLANCO R, RODRIGUEZ-VALVERDE V et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment. Arthritis Rheum, 1998; 41: 1497-504.
21. NESHER G, BERKUN Y, MATES M, BARAS M, RUBINOW A, SONNENBLICK M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum, 2004; 50: 1332-7.
22. LÉVESQUE H. Les effets non lipidiques des statines au cours de l'athérosclérose. Rev Med interne, 2004; 25: 783-5.
23. LOKE YK, BELL A, DERRY S. Aspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient. Br J Clin Pharmacol, 2003; 55: 282-7.